PBE's Holdings Could Mean 30% Gain Potential
July 25, 2016 at 07:40 AM EDT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $51.69 per unit.